Labcorp OmniSeq Insight
Laboratory Corporation of America and OmniSeq have launched the OmniSeq Insight genomic and immune profiling test. The tissue-based test integrates next-generation sequencing technology to advance precision oncology, the firms said. OmniSeq Insight is a pan-cancer solid tumor test for genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression. Results are presented in an easy-to-read report that provides recommendations specific to the patient's results based on a proprietary database that includes information and guidelines from the National Comprehensive Cancer Network. The test is available to US clinicians exclusively through Labcorp and in Canada through Dynacare, a Labcorp company.
Labcorp and OmniSeq, a molecular diagnostics subsidiary of Roswell Park Cancer Institute, signed a distribution agreement in 2017 for OmniSeq's immune profiling and pan-cancer NGS tests, and they extended the deal in 2019.